Streetwise Expert Interviews

Steve Brozak

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next

Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over.

(5/27/15) More >
Read More Streetwise Interviews

Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross

Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, Ross Silver of Vista Partners asserts the upside can be phenomenal. (5/20/15) More >

Newsletter Briefs

"SNGX is an exciting company; it is rare to find a micro cap with such a diverse and broad clinical pipeline." (5/20/15) Soligenix Inc. - The Life Sciences Report Interview with Ross Silver More >

"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >

"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >

"CBMG is a recently transformed company." (5/12/15) Cellular Biomedicine Group Inc. - The Life Sciences Report with John McCamant More >

"HLTH has developed a marketing component to drive more business to its individual centers, and has been very successful." (5/6/15) Nobilis Health Corp. - Interview with Bruce Campbell More >

"RP has a diversified portfolio of technologies, is very focused and is growing rapidly." (4/23/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Michael May More >

"IPD's business model is one we know and love; there is a lot of upside in this company." (4/16/15) ImpediMed Ltd. - The Life Sciences Report Interview with Shane Storey More >

"If MSB's cells work, we're talking about a multibillion-dollar, druglike, blockbuster CHF treatment." (4/8/15) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert More >

Expert Analysis

"We continue to like CTH as a play in the Parkinson's space." (5/27/15) Cynapsus Therapeutics Inc. - Daniel Pearlstein, M Partners More >

"OMER's Omidria is one step closer to European Union approval." (5/26/15) Omeros Corp. - Thomas Yip, MLV & Co More >

"SNGX has up to $50.5M in contracts and grants to support its research." (5/20/15) Soligenix Inc. - Ross Silver, Vista Partners More >

"HLTH's expertise in direct-to-patient marketing is unique." (5/21/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"In SNSS' VALOR study, subgroups showed improved overall survival." (5/21/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We are initiating STEM with a Buy rating." (5/18/15) StemCells Inc. - Ching-Yi Lin, H.C. Wainwright & Co. More >

"Multiple catalysts for SNGX are coming in 2015." (5/18/15) Soligenix Inc. - Jason Kolbert, Maxim Group More >

"NHC's Q1/15 revenue beat can be attributed to strong case volumes." (5/15/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >